Psychiatric Genomics Consortium

The Psychiatric Genomics Consortium (PGC) is an international consortium of scientists dedicated to conducting meta- and mega-analyses of genomic-wide genetic data, with a focus on psychiatric disorders. It is the largest psychiatric consortium ever created,[1] including over 800 researchers from 38 countries as of 2019.[2] Its goal is to generate information about the genetics of psychiatric conditions that will be "actionable", that is, "genetic findings whose biological implications can be used to improve diagnosis, develop rational therapeutics, and craft mechanistic approaches to primary prevention".[1] The consortium makes the main findings from its research freely available for use by other researchers.[3]

  1. ^ a b Sullivan, Patrick F.; Agrawal, Arpana; Bulik, Cynthia M.; Andreassen, Ole A.; Børglum, Anders D.; Breen, Gerome; Cichon, Sven; Edenberg, Howard J.; Faraone, Stephen V. (2018-01-01). "Psychiatric Genomics: An Update and an Agenda". The American Journal of Psychiatry. 175 (1): 15–27. doi:10.1176/appi.ajp.2017.17030283. ISSN 1535-7228. PMC 5756100. PMID 28969442.
  2. ^ Cite error: The named reference about was invoked but never defined (see the help page).
  3. ^ Corvin, Aiden; Sullivan, Patrick F. (May 2016). "What Next in Schizophrenia Genetics for the Psychiatric Genomics Consortium?". Schizophrenia Bulletin. 42 (3): 538–541. doi:10.1093/schbul/sbw014. ISSN 0586-7614. PMC 4838114. PMID 26994396.